In economics, a luxury good (or upmarket good) is a good for which demand increases more than what is proportional as income rises, so that expenditures on the good become a greater proportion of overall spending. Luxury goods are in contrast to necessity goods, where demand increases proportionally less than income.[1] Luxury goods is often used synonymously with superior goods.
Definition and etymology
The word "luxury" derives from the Latin verb luxor meaning to overextend or strain. From this the noun luxuria and verb luxurio developed, "indicating immoderate growth, swelling, ... in persons and animals, willful or unruly behavior, disregard for moral restraints, and licensciousness", and the term has had negative connotations for most of its long history.[2] One definition in the OED is a "thing desirable but not necessary". A luxury good can be identified by comparing the demand for the good at one point in time against the demand for the good at a different point in time, at a different income level. When personal income increases, demand for luxury goods increases even more than income does.
Conversely, when personal income decreases, demand for luxury goods drops even more than income does.[3] For example, if income rises 1%, and the demand for a product rises 2%, then the product is a luxury good. This contrasts with necessity goods, or basic goods, for which demand stays the same or decreases only slightly as income decreases.[3]
Scope of the term
With increasing accessibility to luxury goods,[4] new product categories have been created within the luxury market, called "accessible luxury" or "mass luxury". These are meant specifically for the middle class, sometimes called the "aspiring class" in this context. Because luxury has now diffused into the masses, defining the word has become more difficult.[5]
Whereas luxury often refers to a certain types of products, luxury is not restricted to physical goods; services can also be luxury. Likewise, from the consumer perspective, luxury is an experience that has been defined as "hedonic escapism."[6]
Confusion with normal goods
"Superior goods" is the gradable antonym of "inferior goods". If the quantity of an item demanded increases with income, but not by enough to increase the share of the budget spent on it, then it is only a normal good and is not a superior good. Consumption of all normal goods increases as income increases. For example, if income increases by 50%, then consumption will increase (maybe by only 1%, maybe by 40%, maybe by 70%). A superior good is a normal good for which the proportional consumption increase exceeds the proportional income increase. So, if income increases by 50% then consumption of a superior good will increase by more than 50% (maybe 51%, maybe 70%).
In economics terminology, all goods with an income elasticity of demand greater than zero are "normal", but only the subset having income elasticity of demand > 1 are "superior".[7]
Some articles in the microeconomics discipline use the term superior-good as an alternative to an inferior good, thus making "superior goods" and "normal goods" synonymous. Where this is done, a product making up an increasing share of spending under income increases is often called an ultra-superior good.[citation needed]
Art history
Though often verging on the meaningless in modern marketing, "luxury" remains a legitimate and current technical term in art history for objects that are especially highly decorated to very high standards and use expensive materials. The term is especially used for medieval manuscripts to distinguish between practical working books for normal use, and fully illuminated manuscripts, that were often bound in treasure bindings with metalwork and jewels. These are often much larger, with less text on each page and many illustrations, and if liturgical texts were originally usually kept on the altar or sacristy rather any library that the church or monastery who owned them may have had. Secular luxury manuscripts were commissioned by the very wealthy and differed in the same ways from cheaper books.[8]
"Luxury" and "luxury arts" may be used for other applied arts where both utilitarian and luxury versions of the same types of objects were made. This might cover metalwork, ceramics, glass, arms and armor, and a wide range of objects.[9] It is much less used for objects from the fine arts, with no function beyond being an artwork: paintings, drawings, and sculpture, even though the disparity in cost between an expensive and cheap work may have been as large.[10]
Market
Characteristics
Luxury goods have high income elasticity of demand: as people become wealthier, they will buy proportionately more luxury goods. This also means, however, that should there be a decline in income, its demand will drop more than proportionately. The income elasticity of demand is not constant with respect to income and may change signs at different levels of income. That is to say, a luxury good may become a necessity good or even an inferior good at different income levels.
Some luxury products have been claimed to be examples of Veblen goods, with a positive price elasticity of demand: for example, making a perfume more expensive can increase its perceived value as a luxury good to such an extent that sales can go up, rather than down. However, Veblen goods are not synonymous with luxury goods.
Although the technical term luxury good is independent of the goods' quality, they are generally considered to be goods at the highest end of the market in terms of quality and price. Many markets have a luxury segment including, for example, luxury versions of automobiles, yachts, wine, bottled water, coffee, tea, foods, watches, clothes, jewelry, and high fidelity sound equipment.[11] Luxuries may be services. The hiring of full-time or live-in domestic servants is a luxury reflecting disparities of income. Some financial services, especially in some brokerage houses, can be considered luxury services by default because persons in lower-income brackets generally do not use them.
Luxury goods often have special luxury packaging to differentiate the products from mainstream competitors.
Trends
Originally, luxury goods were available only to the very wealthy and "aristocratic world of old money" that offered them a history of tradition, superior quality, along with a pampered buying experience.[12] Luxury goods have been transformed by a shift from custom-made (bespoke) works with exclusive distribution practices by specialized, quality-minded family-run and small businesses to a mass production of specialty branded goods by profit-focused large corporations and marketers.[12] The trend in modern luxury is simply a product or service that is marketed, packaged, and sold by global corporations that are focused "on growth, visibility, brand awareness, advertising, and, above all, profits."[12] Increasingly, luxury logos are now available to all consumers at a premium price across the world including online.[13]
Global consumer companies, such as Procter & Gamble, are also attracted to the industry, due to the difficulty of making a profit in the mass consumer goods market.[14] The customer base for various luxury goods continue to be more culturally diversified, and this presents more unseen challenges and new opportunities to companies in this industry.[15]
There are several trends in luxury:[16]
- Democratization of luxury. Also known as masstige (from mass-prestige), is a marketing strategy that aims to make brands prestigious while retaining its affordability. [17]
- Globalization: Consumers in some countries are becoming wealthier, thus new markets are opening for luxury marketers.[18] Reports by consulting agencies like McKinsey predicted that East Asia will become the world’s largest personal luxury goods market, and China will consume half the global market value of luxury goods.[19][20]
- Consolidation: Consolidation involves the growth of big companies and ownership of brands across many segments of luxury products. Examples include Kering, LVMH, and Richemont, which dominate the market in areas ranging from luxury drinks to fashion and cosmetics.[21]
- Luxury brand collaborations. This marketing strategy demonstrates the potential of unexpected partnerships and co-branding opportunities between luxury brands and an unconventional partner seemingly at the opposite end of the design spectrum.[20] Collaborations include pairings of luxury brands like Fendi x Versace but also pairings with streetwear brands including skateboarding brand Supreme x LVMH, with celebrities such as Bad Bunny x Adidas, anime characters like Doraemon x Gucci, and now video game franchises like Fortnite x Balenciaga.[22] The collaborations are often limited edition collections.
Size
The luxury goods market has been on an upward climb for many years. Apart from the setback caused by the 1997 Asian Financial Crisis, the industry has performed well, particularly in 2000. In that year, the world luxury goods market was worth close to $170 billion and grew 7.9 percent.[23] The United States has been the largest regional market for luxury goods and is estimated to continue to be the leading personal luxury goods market in 2013, with a value of 62.5 billion euros.[citation needed] The largest sector in this category was luxury drinks, including premium whisky, champagne, and cognac. This sector was the only one that suffered a decline in value (-0.9 percent).[citation needed] The watches and jewelry section showed the strongest performance, growing in value by 23.3 percent, while the clothing and accessories section grew 11.6 percent between 1996 and 2000, to $32.8 billion. The largest ten markets for luxury goods account for 83 percent of overall sales, and include Japan, China, United States, Russia, Germany, Italy, France, United Kingdom, Brazil, Spain, and Switzerland.[citation needed]
In 2012, China surpassed Japan as the world's largest luxury market.[24] China's luxury consumption accounts for over 25% of the global market.[25] According to the Global Wealth and Lifestyle Report 2020, Hong Kong, Shanghai, Tokyo and Singapore were four of the five most expensive cities for luxury goods in Asia.[26] In 2014, the luxury sector was expected to grow over the following 10 years because of 440 million consumers spending a total of 880 billion euros, or $1.2 trillion.[27]
Advertising
The advertising expenditure for the average luxury brand is 5-15% of sales revenue, or about 25% with the inclusion of other communications such as public relations, events, and sponsorships.[28]
A rather small group in comparison, the wealthy tend to be extremely influential.[29] Once a brand gets an "endorsement" from members of this group, then the brand can be defined as a true "luxury" brand. An example of different product lines in the same brand is found in the automotive industry, with "entry-level" cars marketed to younger, less wealthy consumers, and higher-cost models for older and more wealthy consumers.[30]
Economics
In economics, superior goods or luxury goods make up a larger proportion of consumption as income rises, and therefore are a type of normal goods in consumer theory. Such a good must possess two economic characteristics: it must be scarce, and, along with that, it must have a high price.[31] The scarcity of the good can be natural or artificial; however, the general population (i.e., consumers) must recognize the good as distinguishably better. Possession of such a good usually signifies "superiority" in resources, and usually is accompanied by prestige.
A Veblen good is a superior good with a prestige value so high that a price decline might lower demand. Veblen's contribution is demonstrated by the significance of the Veblen effect, which refers to the phenomenon of people purchasing costly items even when more affordable options that provide similar levels of satisfaction are available.[32]
The income elasticity of a superior good is above one by definition, because it raises the expenditure share as income rises. A superior good also may be a luxury good that is not purchased at all below a certain level of income. Examples would include smoked salmon, caviar,[31] and most other delicacies. On the other hand, superior goods may have a wide quality distribution, such as wine and holidays. However, though the number of such goods consumed may stay constant even with rising wealth, the level of spending will go up, to secure a better experience.
A higher income inequality leads to higher consumption of luxury goods because of status anxiety.[33]
Socioeconomic significance
Several manufactured products attain the status of "luxury goods" due to their design, quality, durability, or performance which are superior to the comparable substitutes.[34]
There are also goods that are perceived as luxurious by the public, simply because they play the role of status symbols, as such goods tend to signify the purchasing power of those who acquire them.[citation needed] These items, while not necessarily being better (in quality, performance, or appearance) than their less expensive substitutes, are purchased with the main purpose of displaying wealth or income of their owners.[citation needed] These kinds of goods are the objects of a socio-economic phenomenon called conspicuous consumption and commonly include luxury vehicles, watches, jewelry, designer clothing, yachts, private jets, corporate helicopters as well as large residences, urban mansions, and country houses.[citation needed]
Luxury brands
The idea of a luxury brand is not necessarily a product or a price point, but a mindset where core values that are expressed by a brand are directly connected to the producer's dedication and alignment to perceptions of quality with its customers' values and aspirations.[35] Thus, it is these target customers, not the product, that make a luxury brand.[35] Brands that are considered luxury connect with their customers by communicating that they are at the top of their class or considered the best in their field.[36] Furthermore, these brands must deliver - in some meaningful way - measurably better performance.[36] What consumers perceive as luxurious brands and products change over the years, but there appear to be three main drivers: (1) a high price, especially when compared to other brands within its segment; (2) limited supply, in that a brand may not need to be expensive, but it arguably should not be easily obtainable and contributing to the customers' feeling that they have something special; and (3) endorsement by celebrities, which can make a brand or particular products more appealing for consumers and thus more "luxurious" in their minds.[37] Two additional elements of luxury brands include special packaging and personalization.[37] These differentiating elements distance the brands from the mass market and thus provide them with a unique feeling and user experience as well as a special and memorable "luxury feel" for customers.[37]
Examples include LVMH, the largest luxury goods producer in the world with over fifty brands (including Louis Vuitton)[38] and sales of €42.6 billion in 2017,[39] Kering, which made €15.9 billion in revenue for a net income of €2.3 billion in 2019,[40] and Richemont.
The concept of a luxury brand is now so popular that it is used in almost every retail, manufacturing, and service sector.[41] New marketing concepts such as "mass-luxury" or "hyper luxury" further blur the definition of what is a luxury product, a luxury brand, or a luxury company.[41] Lately, luxury brands extending their reach to young consumers through unconventional luxury brand collaborations in which luxury brands partner with non-luxury brands seemingly at the opposite spectrum of design, image, and value.[20] For example, luxury fashion houses partner with streetwear brands and video games.[42]
Luxury department stores
Since the development of mass-market "luxury" brands in the 1800s. Extraordinary places will be the factor of development that can be achieved by enabling the conversion of items from the mass-market to the luxury market.
Many innovative technologies are being added to mass-market products and then transformed into luxury items to be placed in department stores.[43]
Department stores dedicated to selling all major luxury brands have opened up in most major cities around the world. Le Bon Marché in Paris, France is credited as one of the first of its kind.
In the United States, the development of luxury-oriented department stores not only changed the retail industry, but also ushered the idea of freedom through consumerism, and a new opportunity for middle- and upper-class women.[44]
Luxury shopping districts
Fashion brands within the luxury goods market tend to be concentrated in exclusive or affluent districts of cities around the world. These include:
- Amsterdam's P.C. Hooftstraat
- Abu Dhabi's Saadiyat Island
- Athens Voukourestiou Street and Kolonaki district
- Auckland's Orakei Local Board area
- Bangalore's UB City
- Bangkok's Pathumwan
- Barcelona's Passeig de Gràcia
- Beijing's Yabaolu
- Berlin's Kurfürstendamm
- Bogotá's Zona T
- Boston's Newbury Street
- Brisbane's Teneriffe
- Brussels Louizalaan/Avenue Louise
- Budapest's Rózsadomb district
- Buenos Aires's Recoleta
- Cairo's Zamalek
- Cartagena's Bocagrande
- Chicago's Oak Street
- Dubai's Jumeirah, Al Barsha and Jumeirah districts
- Dublin's Dublin 4 district
- Düsseldorf's Königsallee
- Florence's Via de' Tornabuoni
- Frankfurt's Freßgass
- Guangzhou's Haizhu District
- Hamburg's Neuer Wall
- Hanoi's Hang Bac in Hoàn Kiếm District
- Hong Kong's Central, Tsim Sha Tsui
- Istanbul's Abdi İpekçi Street and İstinye Park
- Jakarta's Menteng and Kebayoran Baru
- Johannesburg's Sandton (Nelson Mandela Square)
- Kuala Lumpur's Bukit Bintang and KLCC
- Las Vegas's Strip
- Leeds Victoria Quarter
- Lisbon's Avenida da Liberdade
- London's Bond Street and Sloane Street
- Los Angeles Beverly Hills (Rodeo Drive)
- Madrid's Calle de Serrano
- Manila's Ayala Avenue
- Medellín's El Poblado
- Melbourne's Collins Street
- Montreal's Rue Sainte-Catherine
- Mexico City's Avenida Presidente Masaryk
- Miami's Star Island and Coral Gables
- Milan's Via Monte Napoleone
- Moscow's Tverskaya Street and Stoleshnikov Lane
- Munich's Maximilianstraße
- New York's Madison Avenue, Fifth Avenue and SoHo
- Paris Champs-Élysées, Avenue Montaigne and Rue du Faubourg Saint-Honoré
- Palm Beach's Worth Avenue[45]
- Panama City's Multiplaza Pacific
- Palm Desert's El Paseo
- Perth's Dalkeith
- Philadelphia's Walnut Street
- Prague's Pařížská
- Rio de Janeiro's Leblon and Copacabana districts
- Rome's Via Condotti
- Reykjavik's Vesturbær and Garðabær
- San Francisco's Union Square
- San Jose's Santana Row
- Santiago's Alonso de Cordoba
- São Paulo's Jardins district and Rua Oscar Freire Street
- Saigon (Ho Chi Minh City)'s District 1
- Seoul's Cheongdam-dong
- Shanghai's Middle Huaihai Road
- Singapore's Orchard Road
- Stockholm's Biblioteksgatan
- Sydney's Castlereagh Street
- Taipei's Xinyi District
- Tel Aviv's Kikar Hamedina
- Tokyo's Ginza and Aoyama
- Toronto's Mink Mile
- Vancouver's Alberni Street
- Vienna's Innere Stadt
- Warsaw's Nowy Świat Street[46]
- Zürich's Bahnhofstrasse
See also
References
[...] as the consumer gets more income, he consumes more of both goods but proportionally more of one good (the luxury good) than of the other (the necessary good).
- Sobczyk, Marcin (4 June 2013). "Luxury Retailers Shop Warsaw". The Wall Street Journal. Retrieved 4 October 2019.
- Lapatin, Kenneth D. S., Luxus, The Sumptuous Arts of Greece and Rome, 2015, J. Paul Getty Museum, ISBN 9781606064221, google books
Further reading
- Chadha, Radha; Husband, Paul (2007). The cult of the luxury brand: inside Asia's love affair with luxury. Nicholas Brealey International. ISBN 9781904838050.
- Wiesing, Lambert (2019). A Philosophy of Luxury. Routledge. ISBN 9780367138417.
https://en.wikipedia.org/wiki/Luxury_goods
Type | Subsidiary[1] |
---|---|
Nasdaq: SHPG | |
ISIN | JE00B2QKY057 |
Industry | Pharmaceuticals |
Predecessor | Shire Pharmaceuticals Group Plc |
Founded | 1986 |
Defunct | 2019 |
Fate | Acquired by Takeda |
Headquarters | Massachusetts, United States[2][3] |
Key people | Flemming Ornskov (CEO) Thomas Dittrich (CFO) |
Revenue | $15,160.6 million (2017)[4] |
$2,455.2 million (2017)[4] | |
$4,271.5 million (2017)[4] | |
Number of employees | 23,044 (2018)[5] |
Parent | Takeda Pharmaceutical Company (2019) |
Website | www.shire.com |
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products were available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts, and Chicago, Illinois, and in Zug, Switzerland. In addition, Shire owns manufacturing sites in Lexington, Massachusetts, and Social Circle, Georgia. Shire's headquarters in Lexington, Massachusetts, will be integrated with Takeda's new U.S. headquarters, which is being relocated from Deerfield, Illinois, to the Boston area.
https://en.wikipedia.org/wiki/Shire_(pharmaceutical_company)
Type | Public |
---|---|
ISIN | US1011371077 |
Industry | Medical device |
Founded | June 29, 1979Watertown, Massachusetts | in
Founders | |
Headquarters | Marlborough, Massachusetts, U.S. |
Key people | Michael F. Mahoney, Chairman and CEO Daniel Brennan, CFO |
Revenue | US$12.68 billion (2022)[1] |
US$1.65 billion (2022)[1] | |
US$698 million (2022)[1] | |
Total assets | US$32.47 billion (2022)[1] |
Total equity | US$17.57 billion (2022)[1] |
Number of employees | c. 51,000[1] (2022) |
Website | bostonscientific |
Boston Scientific Corporation ("BSC"), incorporated in Delaware,[2] is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is widely known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries.[3] With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM subcutaneous implantable defibrillator (S-ICD).[4][5]
https://en.wikipedia.org/wiki/Boston_Scientific
Type | Public company |
---|---|
Industry | |
Founded | 1888Ravenswood, Chicago | (as Abbott Alkaloidal Company) in
Founder | Wallace Calvin Abbott |
Headquarters | Abbott Park, Illinois, US |
Area served | Worldwide |
Key people |
|
Products | Branded generic medicines Medical devices Diagnostic assays Nutritionals |
Revenue | US$43.7 billion (2022) |
US$8.36 billion (2022) | |
US$6.93 billion (2022) | |
Total assets | US$74.4 billion (2022) |
Total equity | US$36.7 billion (2022) |
Number of employees | c. 115,000 (December 2022) |
Website | abbott |
Footnotes / references [2] |
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.[3][4]
Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip.
https://en.wikipedia.org/wiki/Abbott_Laboratories
Type | subsidiary of Merck KGaA |
---|---|
Nasdaq: SIAL | |
Industry | chemistry and biotechnology |
Founded | August 1975 |
Headquarters | Burlington, Massachusetts, United States[2] |
Key people | Matthias Heinzel (Life Science CEO) |
Products | life science technologies and specialty chemicals |
Revenue | EUR€ 6.86 billion (2020)[3] |
Number of employees | more than 20,000 |
Parent | Merck KGaA (100%)[4] |
Website | www |
Sigma-Aldrich (formally MilliporeSigma)[5][6] is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group.
Sigma-Aldrich was created in 1975 by the merger of Sigma Chemical Company and Aldrich Chemical Company. It grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000. The company is headquartered in St. Louis and has operations in approximately 40 countries.[7]
In 2015, the multinational chemical conglomerate Merck Group acquired Sigma-Aldrich for $17 billion.[8] The company is currently a part of Merck's life science business and in combination with Merck's earlier acquired Millipore, operates as MilliporeSigma.[5][6] It is headquartered in Burlington, Massachusetts, United States.[9]
https://en.wikipedia.org/wiki/Sigma-Aldrich
Type | Aktiengesellschaft |
---|---|
Industry | |
Founded | 1 August 1863[1] |
Founder | Friedrich Bayer |
Headquarters | Leverkusen, North Rhine-Westphalia, Germany |
Area served | Worldwide |
Key people |
|
Products |
|
Revenue | €44.081 billion (2021)[2] |
€3.353 billion (2021)[2] | |
€1 billion (2021)[2] | |
Total assets | €120.241 billion (2021)[2] |
Total equity | €33.168 billion (2021)[2] |
Number of employees | 99,637 (2021)[2] |
Website | www |
Bayer AG (/ˈbaɪ.ər/, commonly pronounced /ˈbeɪər/;[3] German: [ˈbaɪɐ]) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company is a component of the EURO STOXX 50 stock market index.[4]
Bayer was founded in 1863 in Barmen as a partnership between dye salesman Friedrich Bayer (1825–1880) and dyer Friedrich Weskott (1821–1876). As was common in this era, the company was established as a dyestuffs producer. The versatility of aniline chemistry led Bayer to expand its business into other areas, and in 1899, Bayer launched the compound acetylsalicylic acid under the trademarked name Aspirin. In 1904, Bayer received a trademark for the "Bayer Cross" logo, which was subsequently stamped onto each aspirin tablet, creating an iconic product that is still sold by Bayer. Other commonly known products initially commercialized by Bayer include heroin, phenobarbital, polyurethanes, and polycarbonates.
In 1925, Bayer merged with five other German companies to form IG Farben, creating the world's largest chemical and pharmaceutical company. Following World War II, the Allied Control Council seized IG Farben's assets[a][5] because of its role in the Nazi war effort and involvement in the Holocaust, including using slave labour from concentration camps and humans for dangerous medical testing, and production of Zyklon B, a chemical used in gas chambers.[6] In 1951, IG Farben was split into its constituent companies, and Bayer was reincorporated as Farbenfabriken Bayer AG. Bayer played a key role in the Wirtschaftswunder in post-war West Germany, quickly regaining its position as one of the world's largest chemical and pharmaceutical corporations.
https://en.wikipedia.org/wiki/Bayer
Type | Public (Aktiengesellschaft) |
---|---|
ISIN | CH0012005267 |
Industry | Pharmaceuticals |
Predecessors |
|
Founded |
|
Founders |
|
Headquarters | Basel, Switzerland (47.5744252°N 7.5764914°E) |
Area served | Worldwide |
Key people |
|
Products | Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...) |
Revenue | US$50.545 billion (2022) |
US$9.197 billion (2022) | |
US$6.955 billion (2022) | |
Total assets | US$117.453 billion (2022) |
Total equity | US$59.423 billion (2022) |
Number of employees | 101,703 (2022) |
Website | www |
Footnotes / references [1][2][3] |
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.[4][5]
Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others.
In March 1996, the companies Ciba-Geigy and Sandoz merged to form Novartis.[6] It was considered the largest corporate merger in history during that time.[6] The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes” (new skills).[6]
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business. The new company also acquired a series of acquisitions in order to strengthen its core businesses.[6]
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA),[7] the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),[8] and the Pharmaceutical Research and Manufacturers of America (PhRMA).[9]
https://en.wikipedia.org/wiki/Novartis
Type | Subsidiary |
---|---|
Industry | Animal healthcare |
Founded |
|
Headquarters | Ingelheim, Germany |
Revenue | €4 billion (2019)[2] |
Number of employees | 10,000 |
Parent | Boehringer Ingelheim |
Website | Official website |
Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets.[3]
https://en.wikipedia.org/wiki/Boehringer_Ingelheim_Animal_Health
https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_mergers_and_acquisitions
Type | Public |
---|---|
| |
ISIN | CA0717341071 |
Industry | Pharmaceuticals |
Founded | 1959 (as ICN Pharmaceuticals) |
Founder | Milan Panić |
Headquarters | Laval, Quebec, Canada |
Key people | Thomas J. Appio (CEO) John Paulson (Chairman) Thomas G. Vadaketh (Executive VP & CFO) John S. Barresi (Senior VP & Controller) |
Revenue | US$8.12 billion (2022) |
US$454 million (2022) | |
US$−212 million (2022) | |
Total assets | US$29.20 billion (2021) |
Total equity | US$−34 million (2021) |
Number of employees | c. 19,600 (2021) |
Subsidiaries |
|
Website | bauschhealth |
Footnotes / references [1] |
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is a Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.
Valeant was originally founded in 1959 as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Securities and Exchange Commission, causing its stock price to plummet more than 90 percent from its peak, while its debt surpassed $30 billion. In July 2018, the name of the company was changed to Bausch Health Companies Inc., in order to distance itself from the public outrage associated with massive price increases introduced by Valeant. At the same time, a new ticker symbol, BHC replaced VRX.[2]
https://en.wikipedia.org/wiki/Bausch_Health
Mylan N.V. | |
Formerly | Milan |
Type | Public (under Dutch law) |
Industry | Pharmaceuticals |
Founded | 1961 in White Sulphur Springs, West Virginia, United States |
Founders | Milan Puskar Don Panoz |
Defunct | November 16, 2020 |
Fate | merged with Upjohn to form Viatris |
Successor | Viatris |
Headquarters | , |
Products | Generic and specialty pharmaceuticals and active pharmaceutical ingredients |
Divisions | see Operations |
Website | www |
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris.[1] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK[2] and a "Global Center" in Canonsburg, Pennsylvania, US.
In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs,[3] and the generics business of Germany-based Merck KGaA.[4] Through these acquisitions, the company grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.[5]
Mylan went public on the OTC market in February 1973.[6] It was listed on the NASDAQ,[7] and its shares were a component of the NASDAQ Biotechnology[8] and the S&P 500 indices.[9]
The company was founded in 1961 and developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.[10]
https://en.wikipedia.org/wiki/Mylan
Type | Subsidiary |
---|---|
Industry | Pharmaceuticals |
Founded | 1989 |
Founders | Randy W. Hamilton Lorin K. Johnson |
Headquarters | |
Key people | Mark McKenna (SVP) Carolyn J. Logan (fmr. CEO) Adam C. Derbyshire (fmr.CFO) |
Parent | Bausch Health |
Website | salix |
Salix Pharmaceuticals, Inc. is an American specialty pharmaceutical company based in Bridgewater, New Jersey.
It is the largest gastroenterology-focused pharmaceutical company in the world. Salix develops prescription drugs and medical devices that prevent and treat various gastrointestinal disorders.
https://en.wikipedia.org/wiki/Salix_Pharmaceuticals
This is a list of the highest known prices paid for philatelic items, including stamps and covers. The current record price for a single stamp is US$9,480,000 paid for the British Guiana 1c magenta.[1][2]
This list is ordered by consumer price index inflation-adjusted value (in bold) in millions of United States dollars in 2022.[note 1] Where necessary, the price is first converted to dollars using the exchange rate at the time the item was sold. The inflation adjustment may change as recent inflation rates are often revised. A list in another currency may be in a slightly different order due to exchange-rate fluctuations. Individual items are listed only once, i.e. for the highest price sold.
https://en.wikipedia.org/wiki/List_of_most_expensive_philatelic_items
No comments:
Post a Comment